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Abstract
Background—Through 2 international traveler-focused surveillance networks (GeoSentinel and 
TropNet), we identified and investigated a large outbreak of acute muscular sarcocystosis (AMS), 
a rarely reported zoonosis caused by a protozoan parasite of the genus Sarcocystis, associated with 
travel to Tioman Island, Malaysia, during 2011–2012.
Methods—Clinicians reporting patients with suspected AMS to GeoSentinel submitted 
demographic, clinical, itinerary, and exposure data. We defined a probable case as travel to 
Tioman Island after 1 March 2011, eosinophilia (>5%), clinical or laboratory-supported myositis, 
and negative trichinellosis serology. Case confirmation required histologic observation of 
sarcocysts or isolation of Sarcocystis species DNA from muscle biopsy.
Results—Sixty-eight patients met the case definition (62 probable and 6 confirmed). All but 2 
resided in Europe; all were tourists and traveled mostly during the summer months. The most 
frequent symptoms reported were myalgia (100%), fatigue (91%), fever (82%), headache (59%), 
and arthralgia (29%); onset clustered during 2 distinct periods: “early” during the second and 
“late” during the sixth week after departure from the island. Blood eosinophilia and elevated 
serum creatinine phosphokinase (CPK) levels were observed beginning during the fifth week after 
departure. Sarcocystis nesbitti DNA was recovered from 1 muscle biopsy.
Conclusions—Clinicians evaluating travelers returning ill from Malaysia with myalgia, with or 
without fever, should consider AMS, noting the apparent biphasic aspect of the disease, the later 
onset of elevated CPK and eosinophilia, and the possibility for relapses. The exact source of 
infection among travelers to Tioman Island remains unclear but needs to be determined to prevent 
future illnesses.
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On 25 October 2011, GeoSentinel, the surveillance program of the International Society of 
Travel Medicine (ISTM) and the US Centers for Disease Control and Prevention (CDC) [1], 
was notified of a cluster of ill German patients recently returned from Tioman Island, off the 
eastern coast of peninsular Malaysia (Figure 1) [2, 3]. These patients had an unusual clinical 
presentation: All of them reported fever and significant muscle pain, had blood eosinophilia 
and elevated serum creatinine phosphokinase (CPK) levels, and tested seronegative for 
trichinellosis and toxoplasmosis. A muscle biopsy from one of these patients was diagnostic 
for acute muscular sarcocystosis (AMS), a rarely reported zoonotic infection. The 
GeoSentinel (available at: http://www.istm.org/geosentinel and http://www.istm.org/
eurotravnet) and TropNet (available at: http://www.tropnet.net) networks contacted their 
members and alerted relevant public health authorities to conduct additional case finding. 
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Within days of the network alerts, additional patients were identified, prompting further 
investigation [2, 4].
Human muscular sarcocystosis is caused by an intracellular protozoan parasite of the genus 
Sarcocystis (available at: http://www.cdc.gov/dpdx/sarcocystosis/index.html). First 
described in 1843, approximately 130 species of Sarcocystis have been identified from a 
variety of wild and domestic mammals, birds, and reptiles [5]. These organisms have an 
obligatory 2-host life cycle, alternating between predator and prey (the definitive–
intermediate hosts). Humans are the definitive host for Sarcocystis hominis and Sarcocystis 
suihominis, acquired by eating undercooked sarcocyst-containing beef or pork, respectively. 
Definitive host infection is limited to the intestine and may cause acute gastroenteritis, 
although most infections are probably asymptomatic [6]. Humans can also become the 
accidental dead-end intermediate host for an unknown number of other Sarcocystis species, 
presumably acquired by ingesting sporocyst-containing food or water contaminated with 
feces from infected carnivores. In the intermediate host, generations of reproduction occur in 
the vasculature, ultimately leading to the formation of characteristic cysts (sarcocysts) 
within myocytes of skeletal, cardiac, and, infrequently, smooth muscle.
Until recently, <100 cases of human muscular sarcocystosis were reported in the literature, 
particularly from Malaysia [7–9]. The majority of these cases were diagnosed incidentally in 
asymptomatic persons or in patients whose symptoms were not clearly related to their 
Sarcocystis infection. At most, 10 of these cases had symptomatic AMS [10–13]; an 
additional recent report describes an outbreak involving 89 patients with AMS acquired on 
Pangkor Island, off the west coast of peninsular Malaysia [14]. Effective treatment for this 
disease has not been determined.
The principal objectives of this investigation were to describe the clinical, laboratory, and 
epidemiologic characteristics of this outbreak of AMS. We also sought to identify possible 
sources of infection among the ill travelers, and to alert clinicians to consider AMS when 
evaluating ill returned travelers.
METHODS
Epidemiologic Investigation
GeoSentinel is a global provider-based, traveler-focused sentinel surveillance network 
established collaboratively by ISTM and the CDC [1]. The 57 GeoSentinel sites in 24 
countries consist of travel and tropical medicine clinics that actively monitor travel-related 
morbidity. TropNet is a European travel and tropical medicine research and surveillance 
network [15]. Together, these networks encompass >110 travel and tropical medicine sites 
and >225 participating affiliated sites worldwide.
After the first patients were reported, members of these networks were notified of the 
outbreak through e-mail alerts and other informal channels. In addition, the networks 
communicated to the larger infectious diseases community through ProMED Mail postings 
[16–19] and published outbreak alerts [2, 4]. Relevant global public health authorities were 
also notified. All were encouraged to report patients suspected of having AMS to 
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GeoSentinel. Clinicians were asked to complete 2 structured questionnaires: one for 
demographic and clinical data and one for travel and exposures. They were also asked to 
document the date of onset for a list of symptoms that were based on our experience with the 
first reported patients, as well as a literature review. This outbreak investigation was 
determined to be public health response, and thus institutional review board review was not 
required. All patients gave informed consent.
We report only those patients meeting an intentionally specific outbreak case definition of 
probable or confirmed AMS. A probable case required travel to Tioman Island after 1 March 
2011, with myositis, eosinophilia >500 cells/μL, and negative trichinellosis serology. 
Myositis required at least 1 of the following: a complaint of muscle pain and a CPK level 
>200 IU/L; muscle tenderness documented on physical examination; or histologic evidence 
of myositis in a muscle biopsy. Case confirmation required histologic observation of 
intramuscular cysts compatible with sarcocysts or the isolation of Sarcocystis species DNA 
from a muscle biopsy.
Laboratory Analysis
Diagnostic testing was at the discretion of the clinician but could include complete blood 
counts and differentials, serum biochemical testing, electrocardiography, echocardiography, 
imaging studies, and electromyography. Some patients were tested for specific diseases such 
as malaria, intestinal parasites, toxocariasis, filariasis, and dengue, chikungunya, and 
Epstein-Barr virus infection. Serum samples were requested, and testing at the CDC 
Parasitic Diseases Reference Laboratory for trichinellosis, toxoplasmosis, and 
strongyloidiasis was performed on available samples not previously tested as part of the 
initial clinical evaluation. Sera were also used by the CDC for developing a serological 
assay for human sarcocystosis using both whole digested merozoites and recombinant 
surface peptides of Sarcocystis neurona.
At the discretion of the clinician, some patients underwent muscle biopsy. All biopsies were 
examined histologically by a pathologist at the institution where collected. When possible, 
tissue blocks, frozen tissue, and extracted DNA cryoprecipitate were sent to the CDC 
Infectious Diseases Pathology Branch for additional examination, including histopathology, 
polymerase chain reaction (PCR) detection, and DNA sequencing analysis of Sarcocystis 
species 18S ribosomal RNA (rRNA) amplicons. For histopathologic examination, 3-μm 
sections were cut from formalin-fixed, paraffin-embedded muscle biopsy specimens and 
stained with hematoxylin and eosin. For electron microscopy (EM), a paraffin section was 
embedded in Epon-Araldite epoxy resin, removed from the slide and glued to a blank EM 
block, sectioned and stained, and examined in an FEI Tecnai Spirit microscope. PCR 
amplification was performed with a primer pair designed to amplify a fragment of 
approximately 800 base pairs from the 18S rRNA gene of different species of Sarcocystis 
[20]. Amplicons were sequenced by using BigDye version 3.1 chemistry (Applied 
Biosystems), and sequence data were analyzed as previously described [21].
Statistical Analysis
Descriptive statistics were estimated using SAS software, version 9.2 (SAS Institute).
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RESULTS
Epidemiologic Characteristics of Case Patients
Demographic and Travel Characteristics—From October 2011 through April 2013, 
99 ill persons who returned home after travel to Tioman Island were reported to GeoSentinel 
as having suspected AMS. Overall, 68 (69%) patients met the case definition and were 
included in the analysis; 62 were probable and 6 were confirmed cases. The median age of 
these patients was 34 years (range, 4–72 years); 39 (57%) were female. Of the 31 who did 
not meet the case definition, 24 did not satisfy criteria for myositis and 5 did not have 
eosinophilia, trichinellosis testing, or both.
More than three-quarters of the case patients resided in either Germany (43%) or France 
(34%). Fourteen (21%) lived elsewhere in Europe (6 in the Netherlands, 3 in Switzerland, 2 
each in Belgium and Spain, and 1 in Italy); the 2 non-Europeans resided in Canada and 
Singapore. Most traveled to Tioman Island during the European summer months (Figure 2); 
all were tourists. The median stay was 5 days (range, 3–16 days), with 49 (72%) of the 
travelers staying <7 days.
Exposures—Complete travel and exposure data were submitted from 61 (90%) case 
patients. Most lodging, eating, and recreational activities were concentrated on the northwest 
coast of Tioman Island; no single village or attraction was visited by >40 (68%, data missing 
for 2) case patients (Figure 1). All travelers reported eating at restaurants and lodging at 
resorts, hotels, huts, or bungalows; no single eating or lodging establishment was visited by 
>22 (36%, Table 1). All case patients visited a beach, and all but 1 (98%) reported 
swimming in the ocean. All but 1 patient reported consuming drinks with ice, and most ate 
fresh produce that might have been washed with unsafe water and/or brushed their teeth 
using tap water. Cats were frequently observed in tourist areas. Reptiles (including snakes 
and lizards) and monkeys were infrequently contacted.
Clinical and Laboratory Findings
Case patients first became ill a median of 11 days (range, 0–40 days) after departing from 
Tioman Island. The most frequent symptoms reported among the 68 case patients were 
myalgia (100%), fatigue (91%), fever (82%), headache (59%), and arthralgia (29%); other 
symptoms were less frequently reported (Figure 3). Patients were first evaluated by the 
reporting clinician at different points during the course of their illness; physical examination 
data were collected only on that first visit, which was a median of 44 days (range, 12–79 
days) after departing from the island. Twenty-nine of 55 (53%) case patients were febrile 
(temperature ≥38°C); 19 of these had a temperature ≥39°C. Muscle tenderness was present 
among 47 of 64 (73%) and was described as moderate or severe in 32 (68%). Thirty-eight of 
64 (88%) had tenderness involving their extremities; 1 reported tenderness of the masseter 
muscle of the face and another of the tongue. Skin rash, lung findings, and lymphadenopathy 
were each found in ≤3 patients. One patient reported subcutaneous nodules on the chin and 
neck that resolved prior to presentation, and another had muscle fasciculations involving all 
4 extremities. One patient had a thrombosis of the left sigmoidal and transverse sinuses 
followed by pulmonary emboli; no clotting abnormality was found, and a sarcocystosis-
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related vasculitis could not be ruled out. One patient was pregnant at the time of infection; 
she experienced no complications. No patient was known to have an underlying medical 
condition (such as immunosuppression) that would have been expected to have affected the 
infection. At least 7 case patients (10%) were hospitalized; none required intensive care.
Onset of the 5 most frequent symptoms appeared to cluster during 2 distinct periods: early 
during the second and late during the sixth week after departure (Figure 4A). No other 
symptom showed this pattern. To account for persons presenting at different times during 
the course of their illness, we also restricted the analysis to those who sought care after the 
fourth postdeparture week; the biphasic symptom-onset pattern persisted. For 25 (37%) 
patients, the illness was described as phasic, intermittent, or waxing–waning in character, 
with periods of symptoms separated by a period of relative improvement.
Although few absolute eosinophil counts or serum CPK levels were performed during the 
first 4 postdeparture weeks, elevations in both were noted most frequently during the late 
period, after the fourth week postdeparture (Figure 4B and 4C). Of 10 case patients with a 
mildly elevated CPK-myocardial band (MB) fraction, 8 had a normal electrocardiogram 
(ECG), echocardiogram, or troponin, and none were thought to have cardiac pathology. One 
patient with a normal CPK-MB fraction, troponin, and ECG on presentation had an 
echocardiogram showing mild dilatation of right ventricular outflow and was thought 
clinically to have developed mild myocarditis. Eighteen (26%) case patients had positive 
Toxoplasma immunoglobulin G, but all those tested were immunoglobulin M negative (6 
unknown). Strongyloides serology was positive in 4 (6%, 2 unknown). Attempts to develop 
and validate a serologic assay for human Sarcocystis species infection were unsuccessful 
due to inconsistent reactivity of sera from patients with confirmed sarcocystosis and cross-
reactivity of sera from patients with known toxoplasmosis.
Patients were treated with a range of antiparasitic agents, including albendazole, as well as 
oral steroids. Some clinicians reported symptom improvement on oral steroids, although we 
could not determine whether improvement was due to the medication or the natural course 
of the illness. The patient with mild myocarditis was treated with oral steroids and 
improved, although causality could not be established.
Histopathology and Species Identification—Fifteen patients had a muscle biopsy 
performed a median of 60 days postdeparture (range, 39–92 days). All tissue samples were 
examined histologically by a pathologist where collected. The CDC received tissue from a 
total of 14 (93%) biopsied patients, as tissue blocks, extracted DNA cryoprecipitate, frozen 
tissue, and/or prepared slides. Photographs of representative histopathology were received 
from 8 patients, 1 from the patient from whom tissue was not available. In all samples and 
photographs examined, histopathology showed inflammation that was predominantly 
perivascular within the endomysium and perimysium with a wide range of severity, from 
rare foci of predominantly lymphohistiocytic inflammation to more frequent foci of mixed 
inflammation (Figure 5A). Sarcocysts were observed histologically in the muscle of only 6 
patients (40%), despite intensive searches including examination of >60 sections from a 
single muscle biopsy sample in which a lone sarcocyst was observed by a pathologist at the 
point where collected. When present, intramyocytic sarcocysts were characterized by single, 
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large (up to 100 μm in width and several hundred micrometers in length), thin-walled, 
septated cysts containing innumerable, crescent-shaped bradyzoites that were approximately 
4 × 8 μm (Figure 5B); no inflammation was observed immediately adjacent to any sarcocyst. 
By EM, large cysts were found embedded in skeletal muscle; they contained numerous, 
approximately 3.5 μm bradyzoites (Figure 5C). The cyst wall demonstrated short, undulating 
type 1 protrusions (Figure 5D) [5].
Ten patients had PCR testing for Sarcocystis species DNA; 1 biopsy sample, also with 
sarcocysts visible on histopathology, was positive. The sequencing analysis of the amplified 
fragment showed 100% similarity with the 18S rRNA gene from Sarcocystis nesbitti 
(GenBank accession number HF544323).
DISCUSSION
We report 68 travelers with AMS acquired while vacationing on Tioman Island, Malaysia. 
The spectrum of AMS in humans is broad: from asymptomatic, which may characterize 
most infected patients [7–9], to severe and relapsing illness lasting years [11]. Comparable 
with other reports, the majority of the Tioman Island patients experienced muscle pain, 
fatigue, fever, and headache. In contrast, we did not find cough, rash, lymphadenopathy, 
swelling, facial tenderness, subcutaneous nodules, or cardiac abnormalities to be prominent, 
although patients were not examined at standardized intervals [10–14].
Onset of symptoms occurred in 2 distinct phases: early (beginning within the second week 
postdeparture) and late (beginning within the sixth week postdeparture). As others have 
reported, more than one-third of our patients experienced waxing and waning of symptoms 
[11, 14]. We found that the late phase corresponded with a rise in the serum CPK level and 
blood eosinophil count, possibly reflecting the onset of an immune-mediated myositis. All 
15 muscle biopsies showed histologic evidence of varying degrees of diffuse multifocal 
myositis; all were done on or after the 39th day after departure from the island, and none had 
evidence of inflammation immediately adjacent to any observed sarcocyst. As few CPK 
determinations and no biopsies were done within 5 weeks of departure from the island, 
earlier development of myositis cannot be ruled out. The lack of clinical suspicion, reflected 
by the paucity of serum CPK and biopsy data in the early weeks, however, suggests that this 
is unlikely.
The phasic nature of AMS in humans reported here is well characterized in animals with 
experimentally induced intermediate-host infections [5]. Signs and symptoms of disease in 
animals reflect the stages of development and the migratory trajectories of the parasite as it 
passes from the intestine via the vascular endothelium to its final destination within the 
myocyte. The exact time course, however, depends on the specific species of infecting 
Sarcocystis and the specific host species that is infected [5]. Given the patterns observed 
among the Tioman Island patients, we hypothesize that disease in humans parallels that seen 
in animals. More work is needed to characterize the pathophysiology of disease in humans 
infected by Sarcocystis species as the intermediate host.
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Despite the presence of swimming beaches and lodging across the island, the ill travelers 
concentrated most of their activities on the northwest portion; however, no obvious source 
of infection could be identified through epidemiologic analyses, although nearly all case 
patients reported potential exposure to untreated water. Cats were ubiquitous and were 
frequently observed in tourist areas, with nearly three-quarters of the case patients reporting 
having either touched or fed a cat. Although long-tailed macaques [22] and numerous reptile 
species, including water monitors and a variety of snakes [23], inhabit Tioman Island, few 
patients reported contacts. Interestingly, an environmental evaluation on the island 
conducted by the Malaysia Ministry of Health (MMoH) in response to this outbreak isolated 
Escherichia coli from almost all, and parasites from several, sampled water sources, 
although no Sarcocystis species were recovered [24]. In addition, no Sarcocystis species 
sporocysts were observed in the animal feces that were sampled, including from cats. 
Although the MMoH isolated Toxoplasma gondii from sampled cats, none of the case 
patients identified during this outbreak had evidence of acute toxoplasmosis, as might be 
expected if cats were the source of this outbreak. Notably, the MMoH did not sample any 
local rodent, bird, or reptile species during their survey of the island, and their investigation 
was limited in scope and conducted during the monsoon season, at a time when no 
infections among travelers were being reported [22–25]. Travelers to Tioman Island should 
be advised to practice proper precautions, including avoiding contact with animals, eating 
and drinking safe food and water, and washing hands frequently.
We identified S. nesbitti from the formalin-fixed muscle tissue of a patient with acute 
myositis and multiple sarcocysts observed on microscopic examination of histologic 
sections. This finding corroborates recent data showing that S. nesbitti was recovered from 
the muscle of 2 of 89 acutely ill patients [14]. Sarcocystis nesbitti has been considered to be 
a potential cause of human infections because it infects Southeast Asian species of 
nonhuman primates, including the long-tailed macaque, and because it resembles 
morphologically sarcocysts seen in humans [26–28]. Although the natural life cycle of this 
organism has not yet been definitively determined, evidence is mounting that S. nesbitti has 
a snake species as its natural definitive host [29–31]. An understanding of the natural life 
cycle of this zoonotic parasite would aid the development of preventive measures and 
messaging.
AMS among travelers is largely a clinical diagnosis that requires an understanding of 
symptoms and symptom progression and the geographic risk distribution of the disease. 
Early diagnosis is made difficult by the nonspecific nature of the early phase of the disease 
and the absence of a simple and accurate diagnostic test, such as serology. Diagnosis in the 
later phase may be easier because relatively few infectious diseases are characterized by 
clinical myositis and eosinophilia, the most notable exception being trichinellosis. In 
addition, the biphasic nature of the illness may offer a hint to the clinician. Currently, 
definitive diagnosis requires histologic observation of sarcocysts in or amplification of 
Sarcocystis species DNA by PCR from a muscle biopsy sample. However, we found that 
sarcocysts are likely distributed diffusely and difficult to find. Although there is currently no 
treatment regimen that has been shown to be effective, anti-inflammatory agents may be 
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helpful in the management of pain. The value of specific antiparasitic agents is an area for 
further exploration.
These data have several limitations. At the outset of this investigation, AMS in humans was 
not well characterized and relevant data may have gone unrecorded. Data were gathered 
retrospectively and at different stages of disease, potentially affecting the accuracy of patient 
recall. Many clinicians from a variety of countries and practice settings participated in data 
collection, which may have introduced variability in data consistency. Finally, our methods 
likely identified more severely affected patients. Our data may not reflect disease among all 
patients infected with S. nesbitti, some of whom may have been asymptomatic.
Our data largely corroborate previous descriptions of human sarcocystosis and offer 
important new details on this emerging disease. Foremost among these is the suggestion of a 
2-phase clinical presentation, commencing about 2 and 6 weeks after infection. 
Unfortunately, the outbreak investigation did not lend itself to determining what proportion 
of those infected remain asymptomatic, assessing the various therapeutic measures, or 
determining the typical duration of illness. Clinicians who see posttravel illness should add 
AMS to their differential diagnosis of the ill patient returning from Malaysia with myalgia, 
with or without fever, noting the apparent biphasic aspect of the disease, the later onset of 
elevated CPK and eosinophilia, and the possibility for relapses. Although only 1 biopsy was 
positive by PCR, our work and the work of others suggest S. nesbitti as a cause of human 
AMS. Further studies should focus on confirming the natural life cycle of this organism to 
develop preventive recommendations, following patients along the full course of their 
illnesses, and studying treatment options. To prevent future illnesses among travelers to 
Tioman Island, the exact source of the outbreak needs to be determined and transmission 
interrupted.
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Tioman Island Sarcocystosis Investigation Team
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Erwin Van Den Enden (deceased) and Marjan Van Esbroeck, Department of Clinical 
Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Wayne Ghesquiere, Vancouver 
General Hospital and Vancouver Island Health Authority, Vancouver and Victoria, British 
Columbia, Canada; Duc Nguyen and Marie-Catherine Receveur, Travel Clinics and 
Division of Tropical Medicine–Clinical International Health, Department of Infectious and 
Tropical Medicine, University Hospital Center, Bordeaux, France; François Peyron, Institut 
de Parasitologie et de Mycologie Médicale, Hôpital de la Croix-Rousse, Lyon, France; 
Philippe Parola, University Hospital Institute for Infectious and Tropical Diseases, Aix-
Marseille University and Assistance Publique Hôpitaux de Marseille, Marseille, France; 
Hélène Savini, Department of Tropical and Infectious Diseases, Laveran Military Teaching 
Hospital, Marseille, France; Eric Caumes, AP-HP, Infectious and Tropical Diseases 
Department, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre et Marie Curie 
University, Paris, France; Alice Perignon, AP-HP, Infectious and Tropical Diseases 
Department, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Michel Develoux, Service 
de Maladies Infectieuses et Tropicales, APHP Hôpital Tenon, Université Pierre et Marie 
Curie, Paris, France; Christophe Rapp, Service de Pathologie Infectieuse et Tropicale, 
Hôpital d’Instruction des Armées Bégin, Saint-Mandé, France; Christian A. Keller, 
Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Martin Haditsch, 
Labor Hannover, Hannover, Germany; Wolfgang Güthoff and Ines Liebold, Klinik für 
Gastroenterologie und Infektiologie, Klinikum Ernst von Bergmann, Potsdam, Germany; 
Johannes Schäfer, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany; Federico 
Gobbi, Centre for Tropical Diseases, Hospital Sacro Cuore-Don Calabria, Negrar, Verone, 
Italy; Willemijn Kortmann and Gitte van Twillert, Medisch Centrum Alkmaar, Alkmaar, 
The Netherlands; Abraham Goorhuis, Vanessa Harris, Michèle van Vugt, and Kees Stijnis, 
Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, 
Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; 
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Eleonora Aronica, Department of (Neuro)Pathology, Academic Medical Center, University 
of Amsterdam, Amsterdam, The Netherlands; Lisette van Lieshout and Meta Roestenberg, 
Laboratory for Parasitology, Leiden University Medical Center, Leiden, The Netherlands; 
Jan van Wout, Bronovo Hospital, The Hague, The Netherlands; Timothy Barkham, 
Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore; Poh Lian Lim, 
Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan 
Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Singapore; Christoph 
Hatz, Swiss Tropical and Public Health Institute, Basel, Switzerland; Silvio D. Brugger and 
Hansjakob Furrer, Department of Infectious Diseases, Bern University Hospital, University 
of Bern, Bern, Switzerland; François Chappuis and Yann Michel, Division of International 
and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland; Sanya 
Choochumporn, Bangkok Hospital Medical Center, Thailand; Than Narkwiboonwong, 
Bangkok Samui Hospital, Ko Samui, Thailand; Matthew S. Dryden, Hampshire Hospitals 
Foundation Trust, Royal Hampshire County Hospital, Winchester, Hampshire, UK; Theresa 
Benedict, Sukwan Handali, and Patricia P. Wilkins, Division of Parasitic Diseases and 
Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, 
Georgia; Wun-Ju Shieh and Sherif Zaki, Division of High-Consequence Pathogens and 
Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for 
Disease Control and Prevention, Atlanta, Georgia; Laura Kogelman, Division of Geographic 
Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts; and Steven 
Hatch, Division of Infectious Disease and Immunology, University of Massachusetts 
Medical School, Worcester.
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Figure 1. 
Tioman Island, Malaysia, and locations visited by 68 case patients with acute muscular 
sarcocystosis, 2011–2012. Marker color represents the frequency of visitation to each village 
or attraction for the 61 case patients with these data available; each patient may have visited 
multiple locations. Other locations visited but not mapped include “south of Tekek” (n = 4), 
“between Ayer Batang and Salang” (n = 3), “between Ayer Batang and Genting” (n = 1), 
“Tekek to Juara” (n = 1), “northwest of island” (n = 3), and a snorkeling trip 
circumnavigating the island by boat with multiple stops (n = 1). Tioman Island is not drawn 
to scale relative to the mainland.
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Figure 2. 
Date of departure from Tioman Island, Malaysia, by week, of 68 travelers with probable and 
confirmed acute muscular sarcocystosis, 2011–2012. The date of departure from Tioman 
Island reflects the last possible point of exposure of the traveler to the Sarcocystis species 
parasite. The earliest departure date was 1 May 2011, and the latest was 5 September 2012.
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Figure 3. 
Symptoms among 68 patients with acute muscular sarcocystosis, Tioman Island, Malaysia, 
2011–2012. Shown are the proportions of patients experiencing each symptom at any time 
during the course of their illness. Symptoms reported in <5% of the case patients are not 
shown and include throat pain* (3%), loss of appetite (3%), and stiff neck* (1%). 
*Unsolicited symptom spontaneously reported in the questionnaire narrative.
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Figure 4. 
Timing of specific elements of acute muscular sarcocystosis. A, Onset of the 5 most 
frequently reported symptoms of acute muscular sarcocystosis relative to the number of 
weeks since departing from Tioman Island; onset clustered during the second (early) and the 
sixth (late) postdeparture weeks. More than 1 onset date for at least 1 of these symptoms was 
reported by 15 patients (myalgia [n = 10], fever [n = 7], headache [n = 2], fatigue [n = 1]; 
none for arthralgia). For 25 (37%) patients, the illness was described as phasic, intermittent, 
or waxing–waning in character, with periods of symptoms separated by a period of relative 
improvement. B and C, All blood absolute eosinophil counts and serum creatinine 
phosphokinase (CPK) levels, respectively, for all patients relative to the number of weeks 
since departing Tioman Island. Each case patient may have had >1 of each laboratory 
determination. One absolute eosinophil count of 6200 cells/μL and 1 CPK level of 3900 
U/L, each from a different patient, is not included in B and C, respectively. *Based on the 
case definition, >500 cells/μL is considered elevated. †Based on the case definition, >200 
U/L is considered elevated.
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Figure 5. 
Histopathology and electron microscopy. A, Skeletal muscle (SM) with inflammation 
(arrows) adjacent to a small vessel (v). Inflammation composed of lymphocytes and 
macrophages with small numbers of plasma cells, eosinophils, and rarely neutrophils. 
Original magnification ×400, hematoxylin and eosin staining. B, SM with intramyocytic 
sarcocyst. Note the absence of inflammation surrounding the sarcocyst-containing myocyte. 
Original magnification 400×, hematoxylin and eosin staining. C, Portion of a cyst within 
SM, containing abundant bradyzoites (arrow). D, Higher magnification of the cyst wall, 
showing short protrusions (arrow) and a fairly thin granular layer (GL). Bars = 2 μm (C) and 
500 nm (D). Abbreviations: GL, granular layer; SM, skeletal muscle; v, small vessel.
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Table 1
Exposures Reported by 61 of 68 Case Patients With Acute Muscular Sarcocystosis and With Data Available, 
Tioman Island, Malaysia, 2011–2012
Travel Exposures (n = 61) Frequency %
Transportation to island
 By ferry only 42 69
 By air only 8 13
 Both ferry and air 11 18
Activity exposures
 Ate at restaurantsa 61 100
 Stayed at resort, hotel, hut, or bungalowa 61 100
 Visited a beach 61 100
 Swam in the ocean 60 98
 Swam in freshwater 12 20
 Snorkeled 53 87
 Scuba dived 18 30
Food/water exposuresb
 Drank beverages with ice 60 98
 Ate fresh vegetables or fruits 47 77
 Brushed teeth with tap water 40 66
Animal exposures
 Cats seen in restaurant kitchens, dining rooms, beachesc 37 61
 Touched or fed a cat or kitten 43 72
 Touched or fed a monkey 8 14
 Touched or fed a lizard 8 14
 Touched or fed a dog or puppy 2 4
 Touched or fed a snake or rodent 0 0
Missing values: Swam in fresh water (1), cats seen in restaurant kitchens, dining rooms, beaches (1), touched or fed a monkey (2), touched or fed a 
lizard (4), touched or fed a dog or puppy (4).
aNo single eating or lodging establishment was visited by >22 (36%) of travelers.
bA single patient lacked any of these potential exposures.
cUnsolicited information spontaneously reported in the questionnaire narrative; similar mention was not made for any other animals, including 
reptiles and monkeys.
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